US28414H1032
© PR Newswire
09.12.2025
ELAN
LISTED
NYSE
Elanco Investor Day Defines New Era as Sustainable Growth Company
News Preview
Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target o...
Themefolio
Profiler
Peergroup
© PR Newswire
21.11.2025
ELAN
LISTED
NYSE
Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats
News Preview
EUA to Treat Cats for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment OptionsFirst U.S. Food and Drug Administration Emergency Use Authorization (EUA) granted for New World screwworm in cats, reinforcing Elanco's leadership in feline innovationAction reinforces the FDA's commitment to...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2025
ELAN
LISTED
NYSE
Elanco to Participate in the Upcoming Investor Conferences
News Preview
INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
13.11.2025
ELAN
LISTED
NYSE
Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health
News Preview
Alloy Partners, Elanco and other corporate partners join forces to develop new venture studio
INDIANAPOLIS, Nov. 13, 2025 /PRNewswire/ -- Alloy Partners today announced the launch of OneHealth Studio, a first-of-its-kind venture studio designed specifically to...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
05.11.2025
ELAN
LISTED
NYSE
Elanco Animal Health Reports Third Quarter 2025 Results
News Preview
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target
Third Quarter
2025 Financial Results:...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ELAN
LISTED
NYSE
Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species
News Preview
FDA approves expanded Credelio Quattro and Credelio labels to include prevention of Lyme disease as a result of killing black-legged ticks (lxodes scapularis) and protection against the longhorned tick (Haemaphysalis longicornis), which is rapidly spreading, now reaching 22 states.i
The Compan...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
ELAN
LISTED
NYSE
Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs
News Preview
EUA to Treat Dogs for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options
First FDA emergency use authorization (EUA) ever granted for NWS in dogs
Action reinforces agency's c...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2025
ELAN
LISTED
NYSE
Elanco to Host Investor Day on December 9
News Preview
INDIANAPOLIS, Oct. 16, 2025 /PRNewswire/ -- Elanco Animal Health, Inc. (NYSE: ELAN) will host an Investor Day on Tuesday, December 9, 2025, from approximately 9 a.m. to 12 p.m. Eastern Time in New York City. The event will feature presentations from Elanco's senior leadership team on the company's strategic prior...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2025
ELAN
LISTED
NYSE
Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement
News Preview
GREENFIELD, Ind., Oct. 1, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2025 financial results on Wednesday, November 5, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's perfor...
Themefolio
Profiler
Peergroup
© PR Newswire
23.09.2025
ELAN
LISTED
NYSE
Elanco Announces FDA Approves Improved Zenrelia™ (ilunocitinib tablets) Label, Removing Vaccine-Induced Disease Language
News Preview
FDA now concludes "the totality of evidence supports removal of the risk of fatal vaccine-induced disease from modified live virus vaccines from the labeling"iFurther evaluation of supplemental scientific data drove this FDA update; data now peer-reviewed and publishedReal-world success and experiences from dermatologists and general practice vet...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ELAN
LISTED
NYSE
Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status
News Preview
Credelio Quattro marked $100 million in net sales making it Elanco's fastest pet health blockbuster in history and one of the industry's fastest ever, especially with a single geographic approvalCredelio Quattro joins Experior® as Elanco's second of six recently launched blockbuster-potential products to reach the $100 million annual net sales mi...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2025
ELAN
LISTED
NYSE
Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education
News Preview
Coalition of community leaders creates new initiative that delivers weekly nutritious food, sugar reduction tools, and wellness education to 250 families across Indianapolis
CARMEL, Ind., Aug. 27, 2025 /PRNewswire/ -- Splenda®, a leading global health and wellness brand in sweeteners, has teamed up with Elanco and HATCH, as well as other partners...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
26.08.2025
ELAN
LISTED
NYSE
Elanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
GREENFIELD, Ind., Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 23rd Annual Global Healthcare Conference, September 8-9, 2025. Jeff Simmons, President and CEO, and Bob VanHimbergen, Executive Vice President and CFO, will participate in a fireside chat on Tuesday, September 9 at 8:30 a....
Themefolio
Profiler
Peergroup
© PR Newswire
07.08.2025
ELAN
LISTED
NYSE
Elanco Animal Health Reports Second Quarter 2025 Results
News Preview
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target
Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA...
Themefolio
Profiler
Peergroup
© PR Newswire
24.07.2025
ELAN
LISTED
NYSE
Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs
News Preview
The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the worldLaunch to begin immediately with product in market before the end of Q3 2025GREENFIELD, Ind., July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia...
Themefolio
Profiler
Peergroup
© PR Newswire
10.07.2025
ELAN
LISTED
NYSE
Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement
News Preview
GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance....
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2025
ELAN
LISTED
NYSE
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection
News Preview
TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8.100% virus neutralization against 33 current field isolates.1Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.2,3,4TruCan Ultra CIV complete...
Themefolio
Profiler
Peergroup
© PR Newswire
26.06.2025
ELAN
LISTED
NYSE
Elanco Releases 2024 Impact Report and Introduces New Framework
News Preview
GREENFIELD, Ind., June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, not just improving the lives of animals but also the people who care for them. Reflecting on its purpose and strategic alignment, the report introduce...
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
ELAN
LISTED
NYSE
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)
News Preview
Company expects approval and product supply in market before the end of third quarter
GREENFIELD, Ind., June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP)...
Themefolio
Profiler
Peergroup
© PR Newswire
05.06.2025
ELAN
LISTED
NYSE
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief
News Preview
The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83%...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
ELAN
LISTED
NYSE
Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer
News Preview
GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-ter...
Themefolio
Profiler
Peergroup
© PR Newswire
16.05.2025
ELAN
LISTED
NYSE
Elanco to Participate in the Upcoming Investor Conferences
News Preview
GREENFIELD, Ind., May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
On Thursday, May 22, Jeff Simmons, president and CEO,...
Themefolio
Profiler
Peergroup
© PR Newswire
07.05.2025
ELAN
LISTED
NYSE
Elanco Animal Health Reports First Quarter 2025 Results
News Preview
Accelerating Debt Paydown in 2025
First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage rat...
Themefolio
Profiler
Peergroup
© PR Newswire
05.05.2025
ELAN
LISTED
NYSE
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown
News Preview
GREENFIELD, Ind., May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Black...
Themefolio
Profiler
Peergroup
© PR Newswire
22.04.2025
ELAN
LISTED
NYSE
Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day
News Preview
National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease.Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo.Puppies treated with CPMA had a 93% survival rate and returned home an average of 1.87 days sooner.1,2Elanco's ParvoTr...
Themefolio
Profiler
Peergroup
© PR Newswire
10.04.2025
ELAN
LISTED
NYSE
Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement
News Preview
GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance....
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
ELAN
LISTED
NYSE
Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets
News Preview
GREENFIELD, Ind., March 17, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by the 2025 Annual Meeting of Shareholders:...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
ELAN
LISTED
NYSE
Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results
News Preview
Fourth Quarter 2024 Financial Results:Revenue of $1,020 million, decreased 1% on a reported basis and increased 4% on an organic constant currency basisReported Net Loss of $8 million, Adjusted Net Income of $72 millionAdjusted EBITDA of $177 million, or 17.4% of Revenue, including an approximate $7 million foreign exchange (FX) headwind vs. late...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
ELAN
LISTED
NYSE
Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle
News Preview
GREENFIELD, Ind., Feb. 25, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement with South Dakota-based Medgene to leverage the company's innovative vaccine platform technology. The agreement includes commercialization of a highly pathogenic avian influenza (HPAI) vaccine for use in...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
ELAN
LISTED
NYSE
Elanco to Participate in Upcoming Investor Conferences
News Preview
GREENFIELD, Ind., Feb. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.
On Thursday, February 27, Todd Young, executive...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
ELAN
LISTED
NYSE
Elanco Launches Pet Protect™ From the Makers of Advantage®: Veterinarian-Formulated Supplements for Complete Pet Wellness
News Preview
Pet Protect offers a comprehensive line of veterinarian-formulated, science-backed supplements.The U.S. pet supplement market is growing as pet parents increasingly desire proactive wellness options.Pet Protect features products for both dogs and cats, including joint health, multivitamins, Omega-3, fast-acting calming, allergy and immune support...
Themefolio
Profiler
Peergroup
© PR Newswire
13.02.2025
ELAN
LISTED
NYSE
Elanco Reinforces Commitment to Veterinary and Pet Owner Education
News Preview
GREENFIELD, Ind., Feb. 13, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated issued the following statement regarding its commitment to clear veterinary and pet owner education following a promotional practices warning letter from U.S. Food and Drug Administration (FDA)....
Themefolio
Profiler
Peergroup
© PR Newswire
04.02.2025
ELAN
LISTED
NYSE
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement
News Preview
GREENFIELD, Ind., Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance....
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2025
ELAN
LISTED
NYSE
Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal
News Preview
Hunter, Trooper, Scrappy and Buckaroo find zen by using ZenreliaNewly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes between Zenrelia and Apoquel® (oclacitinib tablet)GREENFIELD, Ind., Jan. 27, 2025 /PRNewswire/ -- Scratching, rubbing, chewing, licking. All signs of an irrit...
Themefolio
Profiler
Peergroup
© PR Newswire
23.01.2025
ELAN
LISTED
NYSE
Now Available: Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Provides Broadest[i] Parasite Protection of Its Kind
News Preview
Six-in-One Parasite Protection in One Chewable TabletSix of Six Potential Blockbusters from Elanco Now In-MarketGREENFIELD, Ind., Jan. 23, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is now available for veterinarians to...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2024
ELAN
LISTED
NYSE
Elanco to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
GREENFIELD, Ind., Dec. 19, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts at 3:00 p.m. PST (6:00 PM EST)....
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2024
ELAN
LISTED
NYSE
ELAN Deadline Today: Rosen Law Firm Urges Elanco Animal Health Incorporated (NYSE: ELAN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Elanco is an “animal health company that develops, manufactures, and...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2024
ELAN
LISTED
NYSE
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) and reminds investors of the December 6, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company...
Themefolio
Profiler
Peergroup
© PR Newswire
25.11.2024
ELAN
LISTED
NYSE
Elanco to Participate in the Upcoming Investor Conferences
News Preview
GREENFIELD, Ind, Nov. 25, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
On Tuesday, December 3, Todd Young, executive vice pre...
Themefolio
Profiler
Peergroup
© PR Newswire
15.11.2024
ELAN
LISTED
NYSE
Elanco Acquires Speke Contract Manufacturing Facility, Securing Key Supply Chain
News Preview
GREENFIELD, Ind., Nov. 15, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom....
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
ELAN
LISTED
NYSE
Elanco Strengthens Board of Directors with Addition of Stacey Ma
News Preview
Ma brings deep manufacturing and innovation expertise
GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufactur...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
ELAN
LISTED
NYSE
Kirby McInerney LLP Notifies Elanco Animal Health Incorporated (ELAN) Investors of Class Action Lawsuit and Encourages Investors to Contact the Firm
News Preview
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Maryland on behalf of those who acquired Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) securities during the period of November 7, 2024 to June 26, 2024, inclusive (“the Class...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
ELAN
LISTED
NYSE
Elanco Animal Health Reports Third Quarter 2024 Results
News Preview
Third Quarter 2024 Financial ResultsRevenue of $1,030 million, organic constant currency growth of 1%Reported Net Income of $364 million, Adjusted Net Income of $66 millionAdjusted EBITDA of $163 million, or 15.8% of RevenueReported EPS of $0.73, Adjusted EPS of $0.13 Net leverage ratio of 4.3x Adjusted EBITDAPre-tax gain of $640 million from Jul...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2024
ELAN
LISTED
NYSE
ELAN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Elanco Animal Health Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2024
ELAN
LISTED
NYSE
ELAN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Elanco Animal Health Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Elanco Animal Health Incorporated (NYSE: ELAN) securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), have until December 6, 2024 to seek appointment as lead plaintiff of the Elanco Animal class action lawsuit....
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2024
ELAN
LISTED
NYSE
ELAN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Elanco Animal Health Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for...
Themefolio
Profiler
Peergroup
© BusinessWire
11.10.2024
ELAN
LISTED
NYSE
ELAN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Elanco Animal Health Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Elanco Animal Health Incorporated (NYSE: ELAN) securities between November 7, 2023 and June 26, 2024, inclusive (the “Class Period”), have until December 6, 2024 to seek appointment as lead plaintiff of the Elanco Animal class action lawsuit. Captioned B...
Themefolio
Profiler
Peergroup
© PR Newswire
10.10.2024
ELAN
LISTED
NYSE
Elanco Confirms Date and Conference Call for Third Quarter 2024 Financial Results Announcement
News Preview
GREENFIELD, Ind., Oct. 10, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance....
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
ELAN
LISTED
NYSE
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Elanco Animal Health Incorporated (ELAN) Investors
News Preview
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Maryland on behalf of those who acquired Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) securities during the period of November 7, 2023 to June 26, 2024, inclusive (“the Class Period”)...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
ELAN
LISTED
NYSE
ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commi...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
ELAN
LISTED
NYSE
Rosen Law Firm Urges Elanco Animal Health Incorporated (NYSE: ELAN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024. Elanco describes itself as an “animal health company that develops, manufactures, and markets products for pets...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
ELAN
LISTED
NYSE
Elanco Receives FDA Approval for Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the Broadest(i) Canine Oral Parasiticide Protection in a Single Monthly Dose
News Preview
Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, heartworms, roundworms, hookwormsii and three different species of tapeworm that other brands skip creating a gap in coverageiiiWarming temperatures and cha...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2024
ELAN
LISTED
NYSE
Elanco Announces FDA Approval and Launch of Zenrelia™ (ilunocitinib tablets), Offering An Effective, Safe Solution in Canine Dermatology
News Preview
U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitisElanco enters the estimated $1.7 billion global canine dermatology market, highly accretive to existing portfolioIn a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibi...
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2024
ELAN
LISTED
NYSE
Elanco Provides Update on Contract Manufacturing Partner
News Preview
GREENFIELD, Ind., Sept. 13, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today provided an update on its relationship with contract manufacturing supplier, TriRx Speke Ltd (TriRx). TriRx today entered into trading administration, a formal insolvency process in the United Kingdom designed to help companies facing severe fina...
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2024
ELAN
LISTED
NYSE
Elanco to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
GREENFIELD, Ind., Aug. 28, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference, September 4-5, 2024. Jeff Simmons, President and CEO, and Todd Young, executive vice president and CFO, will participate in a fireside chat on Thursday, September 5 at 3:20 p.m. ET...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2024
ELAN
LISTED
NYSE
Elanco Announces Credelio Quattro Moves to Final FDA Administrative Review
News Preview
Company's broad spectrum parasiticide on-track for October U.S. approval and first quarter 2025 launch
GREENFIELD, Ind., Aug. 20, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its review of all major and minor technical sections for Credelio Quattro, a...
Themefolio
Profiler
Peergroup
© PR Newswire
15.08.2024
ELAN
LISTED
NYSE
Credelio® (lotilaner) Kills Ticks 2x as Fast as Simparica TRIO® (sarolaner, moxidectin and pyrantel) and NexGard® (afoxolaner)
News Preview
Study finds that the aggressive lone star tick is no match for Credelio
GREENFIELD, Ind., Aug. 15, 2024 /PRNewswire/ -- Parasites & Vectors, a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study demonstrating that Credelio, a prescription flea and tick protection product...
Themefolio
Profiler
Peergroup
© PR Newswire
08.08.2024
ELAN
LISTED
NYSE
Elanco Animal Health Reports Second Quarter 2024 Results
News Preview
Raises Full Year Revenue and Maintains Adjusted EBITDA Guidance Excluding Aqua Divestiture
Second Quarter 2024 Financial ResultsRevenue of $1,184 millionReported Net Loss of $50 million, Adjusted Net Income of $147 millionAdjusted EBITDA of $275 million, or 23.2% of RevenueReported EPS of $(0.10), Adjusted EPS of $0.30 Net leverage ratio of 5.6x...
Themefolio
Profiler
Peergroup
© PR Newswire
18.07.2024
ELAN
LISTED
NYSE
Elanco Confirms Date and Conference Call for Second Quarter 2024 Financial Results Announcement
News Preview
GREENFIELD, Ind., July 18, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2024 financial results on Thursday, August 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance....
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2024
ELAN
LISTED
NYSE
Elanco Completes Sale of Aqua Business
News Preview
Transaction concentrates Elanco's focus on significant value creation opportunities and accelerates deleveraging progress
GREENFIELD, Ind., July 9, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today it has completed the divestiture of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 bil...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
